Robert Montal, MD, visiting researcher, Icahn School of Medicine, Mount Sinai Hospital, discusses advancements regarding systemic therapies in the field of hepatocellular carcinoma (HCC).

Until now, the only systemic therapies that have shown survival benefits in phase III trials are the multikinase inhibitors sorafenib (Nexavar), lenvatinib (Lenvima), and regorafenib (Stivarga). However, now checkpoint inhibitors are available and have changed the landscape for several solid tumors, potentially HCC, Montal explains.

A phase II trial of nivolumab (Opdivo) have shown promising results in advanced patients with an objective response rate upwards of 20%, along with a manageable safety profile. A phase III trial is ongoing. The identification of predictive biomarkers of nivolumab, and checkpoint inhibitors overall, is a complex issue, he adds. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Montal on Systemic Therapy Advancements in HCC